most retail will skedaddle . this is just too painful and there are better opportunities in the market. this company taking frenemy to a whole new level . 2.50 coming
I strongly disagree with each and every syllable of those thoughts. I stand by what I have said previously.
"The NIH extended trial diverts our attention from the progress the Big Pharmas are making getting their mAbs into clinical trials. Another year, or less, of NIH trial testing could mean we lose our ability to maintain CMC compliance, if we can't financially reserve manufacturing capacity, maintain distribution agreements, or fulfill customer demand. It could mean that the FDA approves a Big Pharma mAb, and closes the EUA door.
"Our fate is being wrested from us, with the successful completion of our internal Phase III trial, as the government attempts to commandeer our future."
Seeing this coming doesn't make it any easier to see it arrive. In fact, it has just the opposite effect, and it makes me even madder.
But aside from those points, I have talked about how effectively management has responded to the circumstances.
"That's also why I think the updated trial results, reflecting a mortality Hazard Ratio of 2.22, is so important, and I'm glad to see this highlighted Hazard Ratio being submitted for consideration of the FDA's Scientific Advisory Board...
I'm also hoping that Clinigen is updating our usage results daily on a per-patient basis, and generating thousands of treatments under Compassionate Use."
With the pre-print of our updated results now ready for peer-review on medRx, the medical community will get a much more accurate portrayal of our efficacy, including a significant mortality benefit. I just hope that we will get an update on revenue coming through LenzMAP.
Those are brilliant accomplishments that prove that our management is anything but inept or moronic. They have my continued support, confidence, and gratitude.
News 
Market Data 
Discover 
